CareDx Earnings Call Highlights Growth Amid Reimbursement Risks

CareDx Inc ((CDNA)) has held its Q4 earnings call. Read on for the main highlights of the call.

CareDx’s latest earnings call struck a notably upbeat tone, with management emphasizing accelerating top‑line growth, sharply better cash collections, and a solid margin profile. While near‑term profits will be pressured by investments and reimbursement changes, executives framed these as deliberate choices to support scalable growth and to cushion potential policy and pricing headwinds.

Revenue Growth Accelerates Into Year-End

CareDx posted Q4 2025 revenue of $108.4M, up 25% year over year, underscoring a strong finish to the year. Full‑year revenue reached $379.8M, a 14% increase, signaling that the company is regaining momentum despite reimbursement noise in its core transplant diagnostics markets.

Testing Volumes and Services Drive the Core Engine

Testing demand remained robust, with Q4 volumes of about 53,000 tests, up 17% and supporting Testing Services revenue of $78.4M, up 23%. For 2025, volumes approached 200,000 tests, rising 14% and generating $274.5M in Testing Services revenue, up 10% as CareDx deepens adoption across transplant centers.

Cash Collections Surge and Receivables Tighten

The company highlighted major improvements in revenue cycle management, with full‑year cash collections jumping 32% to $405.6M and Q4 collections up 37% to $115.8M. Accounts receivable fell by $22.5M year over year, while days sales outstanding dropped from 71 to 41 days, materially strengthening cash conversion.

Margins Hold Firm as Profitability Improves

CareDx maintained attractive unit economics, delivering Q4 non‑GAAP gross profit of $74.3M and a 68.5% gross margin. For 2025, gross margin stayed around 69.3%, and adjusted EBITDA climbed 14% to $31.7M, underscoring underlying leverage even as the company invests in growth initiatives.

Pipeline Advances With New Products and Certifications

Management spotlighted a string of product launches, including AlloSure Heart for pediatrics, the AI‑driven Alisure Plus kidney risk model, and the HistoMAP kidney tissue classifier. New lab offerings AlloSeq TX11 and SCOR 7, along with IVDR certification for AlloSeq TX and QType in Europe, broaden the company’s global transplant toolkit.

Cell Therapy Surveillance Shows Promising Data

In cell therapy, the ACROBAT study for the Allaheme assay produced compelling clinical results, detecting relapse a median 41 days earlier with 85% sensitivity and 92% specificity. A positive 6‑month result was linked to a 12‑fold higher relapse risk, and CareDx is targeting CLIA readiness in 2026 with commercial launch planned for early 2027.

High-Growth Adjacent Segments Gain Traction

Beyond core testing, Patient & Digital Solutions revenue surged 47% in Q4 to $16.8M, while Lab Products rose 17% to $13.3M, both outpacing the broader business. For 2025, Patient & Digital Solutions grew 31% to $56.9M and Lab Products climbed 19% to $48.4M, providing diversified, high‑growth revenue streams.

Balance Sheet Strength and Active Capital Returns

CareDx ended the year with $201.4M in cash, equivalents, and marketable securities and no debt, giving it ample flexibility to invest and weather reimbursement shifts. The company returned capital as well, repurchasing $88M of stock in 2025, totaling 5.8M shares, and buying another $12M in Q4 alone.

EBITDA Hit by One-Time Compensation Costs

Q4 adjusted EBITDA slid 34% year over year to $6.5M, as non‑GAAP operating expenses included a $6.7M one‑time cash bonus in lieu of equity grants for non‑executive staff. Management framed this as a discrete item that weighed on quarterly profitability but aligned incentives and should not recur at similar levels.

Reimbursement and Coverage Pressures Loom

Investors face some policy risk, as a draft MolDX local coverage determination for solid organ transplant testing could trim revenue. CareDx modeled a $7.5M half‑year hit in 2026, implying about $15M on a full‑year basis if finalized, while a new PLA code effective early 2026 reduced AlloSure Kidney reimbursement by roughly 4%.

Revenue Per Test Expected to Face Near-Term Drag

Management acknowledged that reimbursement changes and conservative modeling will pressure revenue per test in 2026, which is guided to average in the low $1,400s. This compares with Q4’s reported average revenue per test of $14.80 per unit, signaling a modest but manageable pricing headwind as the mix and codes reset.

Strategic Systems Investments to Temper EBITDA

CareDx is committing about $10M to implement an Epic Enterprise LIMS and associated integrations, with roughly $6M recurring and $4M in implementation costs. These modernization efforts are expected to elevate operating expenses and dampen near‑term EBITDA but should enhance scalability, data integration, and operational efficiency long term.

Conservative Volume Assumptions Underpin Outlook

For 2026, the company guided testing volumes to 220,000–228,000 tests, with a midpoint of 224,000 representing roughly 12% year‑over‑year growth. Management emphasized that it is not banking on procedure volume expansion and is treating upside from initiatives like Epic Aura conservatively, suggesting room for outperformance if trends remain favorable.

Leadership Changes Add a Note of Execution Risk

On the management front, CFO Nathan Smith announced plans to transition after the annual filing, prompting a reshuffle at the top of the finance and operations ranks. Keith Kennedy has been appointed COO and CFO effective late February, introducing some transition risk but also potentially tightening operational and financial coordination.

Guidance Signals Growth With Built-In Caution

For 2026, CareDx guided revenue to $420M–$444M, with a midpoint of $432M implying about 14% growth and Testing Services revenue of $306M–$326M on 220,000–228,000 tests. The company anticipates blended revenue per test starting near $1,400 and averaging in the low $1,400s, gross margins of about 69%–71%, quarterly OpEx around $68M including Epic/LIMS spend, and adjusted EBITDA of $30M–$45M.

CareDx’s earnings call painted a picture of a diagnostics company balancing healthy growth with real but quantified reimbursement and investment headwinds. With strong cash flow, no debt, expanding product lines, and disciplined guidance, the company is positioning itself for scaled growth, though investors will be watching policy decisions and execution on major systems projects closely.